PLCH2

Chr 1

phospholipase C eta 2

Also known as: PLC-L4, PLC-eta2, PLCL4, PLCeta2

Phospholipase C eta 2 cleaves PtdIns(4,5)P2 to generate the second messengers diacylglycerol and inositol 1,4,5-trisphosphate, and may be important for formation and maintenance of neuronal networks in the postnatal brain. Mutations cause neurodevelopmental disorders with autosomal recessive inheritance. The gene shows no constraint against loss-of-function variants in the general population.

Summary from RefSeq, UniProt
Research Assistant →
0
Active trials
1
Pubs (1 yr)
131
P/LP submissions
0%
P/LP missense
0.96
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryPLCH2
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
124 unique Pathogenic / Likely Pathogenic· 272 VUS of 471 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.96LOEUF
pLI 0.000
Z-score 1.80
OE 0.72 (0.550.96)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
1.23Z-score
OE missense 0.87 (0.810.93)
615 obs / 707.3 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.72 (0.550.96)
00.351.4
Missense OE0.87 (0.810.93)
00.61.4
Synonymous OE1.11
01.21.6
LoF obs/exp: 35 / 48.6Missense obs/exp: 615 / 707.3Syn Z: -1.50
DN
0.6746th %ile
GOF
0.72top 25%
LOF
0.4430th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

471 submitted variants in ClinVar

Classification Summary

Pathogenic121
Likely Pathogenic3
VUS272
Likely Benign34
Benign16
121
Pathogenic
3
Likely Pathogenic
272
VUS
34
Likely Benign
16
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
121
0
121
Likely Pathogenic
0
0
3
0
3
VUS
0
254
18
0
272
Likely Benign
0
20
4
10
34
Benign
1
3
4
8
16
Total127715018446

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

PLCH2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC

No open access results found